Temozolomide (TMZ) for progressive primitive brain tumors:: safety at 75 mg/m2 a day for 21 days every 28:: A GICNO (Italian Neuro-Oncology Group) study.

被引：0
|
作者：
Brande, AA
Cavallo, G
Tosoni, A
Ermani, M
Franceschi, E
Scopece, L
Ghimenton, C
Blatt, V
Nicolardi, L
Crinò, L
机构：
[1] Azienda Osped Univ, Padua, Italy
[2] Bellaria Hosp, Bologna, Italy
[3] Verona Hosp, Verona, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：124S / 124S
页数：1
相关论文
共 5 条
  • [1] Temozolomide (TMZ) for 21/28 days in patients with progressive glioblastoma (GBM):: Preliminary results of phase 2 study of GICNO (Italian Neuro-Oncology Group)
    Brandes, A
    Cavallo, G
    Tosoni, A
    Ermani, M
    Scopece, L
    Franceschi, E
    Nicolardi, L
    Talacchi, A
    Blatt, V
    Crinò, L
    NEURO-ONCOLOGY, 2005, 7 (03) : 312 - 312
  • [2] Temozolomide (TMZ) for 21/28 days in patients with progressive glioblastoma (GBM): Preliminary results of phase II study of gicno (Italian neuro-oncology group)
    Tosoni, A.
    Cavallo, G.
    Scopece, L.
    Franceschi, E.
    Nicolardi, L.
    Roma, A.
    Blatt, V.
    Gioia, V.
    Crino, L.
    Brandes, A. A.
    ANNALS OF ONCOLOGY, 2005, 16 : 63 - 63
  • [3] A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
    Weiss, G.
    Donehower, R.
    Westin, E.
    Bence, A.
    Hynes, S.
    Hurt, K.
    EJC SUPPLEMENTS, 2010, 8 (07): : 165 - 165
  • [4] Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
    Glen J. Weiss
    Ross C. Donehower
    Tara Iyengar
    Ramesh K. Ramanathan
    Karen Lewandowski
    Eric Westin
    Karla Hurt
    Scott M. Hynes
    Stephen P. Anthony
    Scott McKane
    Investigational New Drugs, 2013, 31 : 136 - 144
  • [5] Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
    Weiss, Glen J.
    Donehower, Ross C.
    Iyengar, Tara
    Ramanathan, Ramesh K.
    Lewandowski, Karen
    Westin, Eric
    Hurt, Karla
    Hynes, Scott M.
    Anthony, Stephen P.
    McKane, Scott
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 136 - 144
1